Efficacy of treatment with traditional Chinese patent medicine (Fufang E'jiao Syrup) for cancer-related fatigue in patients with advanced cancer: A randomized, double-blinded, placebo-controlled, multicenter trial.

Authors

Shan Shan Gu

Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China

Shan Shan Gu , Yun Xu , Jun J. Mao , Lingyun Sun , Ning Cui , Feiye Wang , Jing Dong , Xingyu Guo , Li Fu , Jinghui Wang , Jiyan Shi , Yumei Zeng , Yidan Hu , Zipei Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.

First Author: Beihua Kong

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial.

First Author: Takahiro Kogawa

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A multicenter, randomized, double-blind phase III clinical study to evaluate the efficacy and safety of KN046 combined with nab-paclitaxel and gemcitabine versus placebo combined with nab-paclitaxel and gemcitabine in patients with advanced pancreatic cancer (ENREACH-PDAC-01).

First Author: Gang Jin

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.

First Author: Yelena Y. Janjigian